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Background.  Systemic inflammation contributes to the development of 
intrapulmonary and extra pulmonary disorders, and as an independent risk factor for 
exacerbation of chronic obstructive pulmonary disease (COPD) has proven. The use 
of corticosteroids as anti-inflammatory agents has limitation for their undesirable side 
effects and different efficacy among the patients. Erdosteine, a mucolytic agent 
widely used in COPD, has been proven able to inhibit several mediators such as 
reactive oxygen species (ROS) and eicosanoids, which are involved in oxidative stress 
and inflammation.  
Objective. This study aimed to discover the effects of erdosteine administration in 
serum C - reactive protein (CRP) level in stable COPD patients. 
Methods. The research was a randomized controlled trial, which compared add-on 
therapy used erdosteine 300 mg bid versus placebo, for 10 days, combined with 
COPD standard treatments. The patients was recruited at RSKP Respira Yogyakarta 
outpatient clinics. Diagnoses were confirmed used spirometry based on GOLD 
criteria. Evaluation of CRP levels was hold before treatment and on the eleventh day, 
used highly sensitive quantitative immunometric assay. 
Result. Thirty-eight legible COPD patients recruited and randomly assigned to 
either erdosteine group or placebo group. One patient in erdosteine group was drop 
out because of exacerbation and one patient from each group were lost to follow up. 
There are 35 subjects (97.1% men, age range 40-77 years, median FEV1 0.83 (0.50-
10.08) L, hs-CRP 0.84 (0.18-18) mg/L) who completed the study, 19 subjects in 
erdosteine and 16 subjects in placebo group. Baseline characteristics were similar 
between two groups. There were no significant decreases in median hs-CRP level in 
erdosteine vs. placebo group at day 11 (-0.10 (-16.16-+4.31) vs. 0.005 (-11.7-+11.03) 
mg/L; p 0.275). In COPD GOLD 3 sub-population, hs-CRP serum level decline was 
greater in erdosteine group compared to placebo (-0.56 (-16.16-+0.44) vs. 0.11 (-11.7- 
+11.03) mg/L;  p 0.03) this might be related to greater oxidative stress in severe 
COPD that makes antioxidative effects of erdosteine reduce CRP more significantly 
in severe COPD.  
Conclusion. Effects of erdosteine supplements, 300 mg bid for 10 days, could 
decrease hs-CRP level in erdosteine insignificantly compared to placebo.  
Keywords: table COPD, C-reactive protein, erdosteine, FEV1, GOLD 
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ABSTRAK
Latar Belakang. Peradangan sistemik berkontribusi terhadap perkembangan gangguan paru 
intrapulmoner dan ekstrapulmoner, dan sebagai faktor risiko independen untuk eksaserbasi 
penyakit paru obstruktif kronik (PPOK) telah terbukti. Penggunaan kortikosteroid sebagai agen 
antiinflamasi memiliki keterbatasan mengenai efek samping yang tidak diinginkan dan hasil yang 
berbeda di antara pasien. Erdosteine, agen mukolitik yang banyak digunakan pada PPOK, telah 
terbukti dapat menghambat beberapa mediator seperti spesies oksigen reaktif (ROS) dan 
eikosanoid, yang terlibat dalam stres oksidatif dan pembengkakan. 
Tujuan. Penelitian ini bertujuan untuk mengetahui efek pemberian erdostein pada tingkat protein 
C-reaktif (CRP) serum pada pasien COPD yang stabil. 
Metode. Penelitian ini merupakan uji coba terkontrol secara acak, yang membandingkan terapi 
tambahan menggunakan erdosteine 300 mg versus plasebo, selama 10 hari, dikombinasikan 
dengan perlakuan standar COPD. Pasien direkrut di klinik rawat jalan RSKP Respira 
Yogyakarta. Diagnosis menggunakan spirometri berdasarkan kriteria GOLD. Evaluasi tingkat 
CRP dilakukan sebelum perawatan dan pada hari kesebelas, menggunakan tes imunometrik 
kuantitatif yang sangat sensitif. 
Hasil. Tiga puluh delapan pasien COPD direkrut dan ditugaskan secara acak pada kelompok 
erdostein atau kelompok plasebo. Satu pasien dalam kelompok erdostine dikeluarkan karena 
adanya eksaserbasi dan satu pasien dari setiap kelompok hilang untuk ditindaklanjuti. Ada 35 
subjek (97,1% pria, rentang usia 40-77 tahun, median FEV1 0,83 (0,50-10,08) L, hs-CRP 
0,84 (0,18-18) mg / L) yang menyelesaikan penelitian, 19 subjek dalam kelompok erdosteine dan 
16 subyek dalam kelompok plasebo. Karakteristik dasar serupa di antara dua kelompok. Tidak 
ada penurunan yang signifikan pada tingkat median hs-CRP pada kelompok erdostein vs plasebo 
pada hari ke 11 (-0,10 (-16,16- + 4,31) vs 0,005 (-11,7- + 11,03) mg / L; p 0,275). Pada 
sub populasi COPD GOLD 3, penurunan kadar serum hs-CRP lebih besar pada kelompok 
erdosteine dibandingkan plasebo (-0,56 (-16,16- + 0,44) vs 0,11  
(-11,7- + 0,03) mg / L; p 0,03) hal ini mungkin terkait dengan stres oksidatif yang lebih besar 
pada COPD berat yang membuat efek antioksidan dari erdosteine mengurangi CRP lebih 
signifikan pada COPD berat. 
Kesimpulan. Efek suplemen erdosteine, 300 mg bid selama 10 hari, dapat menurunkan kadar 
hs-CRP pada erdosteine secara tidak signifikan dibandingkan dengan plasebo. 
 
Kata kunci: tabel COPD, protein C-reaktif, erdostein, FEV1, GOLD 
 
 
Introduction 
A chronic obstructive 
pulmonary disease is a chronic and 
progressive inflammatory disease 
involving not only the lungs but also 
multiple organs and systems outside of 
the lung1,2. Systemic inflammation 
contributes to the pathogenesis of 
pulmonary and extrapulmonary 
disorders of COPD2.  
Systemic inflammation is 
currently regarded as a hallmark of 
COPD and found to contribute to the 
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pathogenesis of pulmonary and 
extrapulmonary disorders PPOK2,4 
Increased systemic inflammation is an 
independent risk factor for acute 
exacerbations of COPD4. Recurrent 
exacerbations lead to decreased quality 
of life, decreased therapeutic response, 
increased progression of disease, as 
well as increased mortality5.  
Dal Negro et al7 found that 
erdosteine, a mucolytic agent, has the 
ability to inhibit multiple mediators 
such as reactive oxygen species (ROS), 
8-isoprostane serum, IL-8 bronchial, 
and eicosanoids which are involved in 
oxidative stress and inflammatory 
process. Through its ability as an 
antioxidant and anti-inflammatory, 
erdosteine expected to improve 
systemic inflammation in stable 
COPD. Improvements are expected 
to slow the systemic inflammatory 
worsening lung function, preventing 
extra pulmonary disorders, improving 
quality of life, as well as prevent 
exacerbations.9, 10, 11 
 
Material and Methods 
This study is a double-blind 
randomized controlled trial. Subjects 
are stable COPD patients in the 
pulmonary clinic of RSKP Respira 
Yogyakarta. Inclusion criteria for the 
study subjects were patients aged ≥ 18 
years, stable COPD category 1, 2, 3, or 
4, and are willing to fill out informed 
consent. Patients did not include the 
categories if they have allergic to 
erdosteine, or mucolytic erdosteine 
and other thiol groups (N-acetyl 
cysteine). In the last 3 days, using 
corticosteroids, liver disorders, kidney 
disorders, infection, suffering 
malignancy, diabetes mellitus, acute 
myocardial infarction, ischemic heart 
disease, hypertension, asthma, cor-
pulmonale, Crohn's disease, a history 
of trauma or undergone surgery in the 
last one month, pregnancy, and 
lactation.  
Subjects who met the 
inclusion and exclusion criteria 
randomize into two different groups, 
receiving 2x300 mg of erdosteine and 
placebo for 10 days. Evaluation of 
serum CRP levels was hold before 
treatment and day 11. Examination of 
serum CRP is done using 
immunometric assay method 
(Immulite 2000R) with result range 
between 0.1 mg/L to 100 mg/L.  
 
Data analysis 
The results of the study were 
analyzed by a computer program. The 
difference of numerical data was 
analyzed using independent t-tes of 
Mann Whitney U test. The difference 
in proportions of categorical data was 
testing by Chi-Square t-test.  
 
Results  
Table 1 showed the basic 
characteristics of study subjects in 
each group. The median decrease in 
serum CRP levels erdosteine groups is 
not statistically greater than placebo 
(Table 2). The proportion of study 
subjects who experienced a decrease 
in serum CRP levels at erdosteine 
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group larger than the placebo group, 
although not statistically significant 
(63.2% vs. 50%, p 0.215). 
In this research, we performed 
sub analysis test to the group of 
subjects with and without systemic 
corticosteroids as well as research 
subjects with GOLD two and three. 
The median change in serum CRP 
levels of erdosteine and placebo 
groups in subjects with systemic 
corticosteroids was -1.03 (-16.16 – (-
0.05)) vs. -0.48 (+0.44 -11.7-) (p 0.26), 
whereas in subjects without systemic 
corticosteroids was 0.05 (-13- + 4.31) 
vs. 0.12 (-0.93- + 11.03) (p 0.285). 
 In the group of COPD 
GOLD 2, there was no significant 
change in serum CRP levels between 
erdosteine and placebo (0.56 ± 2.36 
mg / L vs. -1.24 ± 1.83, p 0.085). In 
the group of COPD GOLD 3, we 
obtained a greater median decrease in 
erdosteine group than in the placebo 
group (Table 4). 
 
Discussion 
 Systemic inflammation is a 
major marker of COPD and is 
thought to be a liaison of the missing 
link between airway dysfunction with 
various systemic complications in 
COPD4,12. Erdosteine is a mucolytic 
agent that has the pleitropic effects, 
namely antibacterial, antioxidant, and 
anti-inflammation13. Through this 
ability, it is expected that erdosteine 
may decrease systemic low-grade 
inflammation that occurs in patients 
with stable COPD. Source of systemic 
inflammation in COPD was not yet 
fully know and was not suspect to be 
multifactorial. Cigarette smoke 
damage to lung tissue.  Lung 
hyperinflation, tissue hypoxia, changes 
in skeletal muscle and bone marrow, 
aging, oxidative stress, as well as 
autoimmune factors thought to 
contribute to systemic inflammation in 
COPD14. Erdosteine allegedly can 
improve the inflammatory process 
indirectly through the detoxification of 
free radicals, increased levels of 
intracellular antioxidant, controlling 
the activation of NF-ĸB, as well as 
decreased production of eicosanoid15. 
Even with erdosteine treatment 
COPD inflammatory pathways other 
than the alleged oxidative stress is 
ongoing.  
This is probably one of the 
causes of the decline of serum hs-CRP 
levels were not significant in this 
study. In both study groups we did 
not find significant differences in 
confounding factors such as gender, 
age, smoking status, degree of GOLD, 
hypertension, arthritis, use of drugs 
such as statins, COX-2 inhibitors, 
inhibitors of the renin-angiotensin-
aldosterone system such as 
angiotensin-converting enzyme 
inhibitors (ACEI) and angiotensin 
receptor blockers (ARBs), beta 
blockers, corticosteroids, and 
hormonal contraceptives. 
Ten percent of COPD patients 
with normal BMI have increased 
relative and absolute fat mass. Adipose 
tissue is proven to generate several 
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adipokines involved in the process 
inflammation4. In this study, we did 
not measure fat mass and fat-free 
mass. Therefore, the possible 
influence of the pro-inflammatory 
adipokines fat mass cannot be 
excluded. 
Antioxidants contained in the 
daily diet such as vitamin C, vitamin 
E, beta-carotene, as well as natural 
products containing flavonoids or 
polyphenols, ginkgo biloba, 
polyunsaturated fatty acids or omega-3 
fatty acids may play a role in the 
management of oxidative stress which 
is triggered by a cigarette and on 
COPD patients15. Antioxidant 
supplements in daily diet and exposure 
to pollutants in the workplace or in 
neighborhood were confounding 
factors that were not analyzed in this 
study 
Sub-analysis test between 
groups of subjects with and without 
systemic corticosteroid therapy in 
erdosteine and placebo groups showed 
no significant differences in serum hs-
CRP levels. Therefore, the 
confounding role of systemic 
corticosteroids may be excluded. On 
the other hand, it showed the 
possibility of steroid resistance in 
study subjects. 
Kluchova et al16 and Kirkham 
& Rahman17 found the relationship 
between the various products of lipid 
peroxidation, protein nitration, and 
the antioxidant activity of glutathione 
peroxidase with COPD severity as 
assessed by FEV1. In subjects with 
COPD GOLD 3 (severe) allegedly 
occur greater oxidative stresses that 
Erdosteine antioxidant effect was 
more pronounced resulting in a 
greater decrease in serum CRP levels.  
Based on the understanding of 
the relationship of oxidative stress 
with the severity of COPD, a decrease 
in serum CRP levels can be seen in 
COPD GOLD 4. However, this 
cannot be assessed in this study 
because there is only one study subject 
with COPD GOLD 4. 
These study limitations are 
several confounding factors cannot be 
controlled or not analyzed such as 
increase at mass, diet, and exposure to 
pollutants in the workplace 
environment or the working 
environment.  
Diagnosis of several 
confounding comorbidities were not 
done accurately as echocardiography 
to rule out pulmonary hypertension or 
cor pulmonale and treadmill test to 
rule out ischemic heart disease. The 
number of study subjects had not 
meet the minimum sample size 
calculation, only 35 subjects 
completed the study. Moreover, sub-
analysis test was not possible at all 
levels of COPD severity as research 
subjects is not divided evenly. 
 
Conclusion 
Erdosteine 300 mg bid for 10 
days in patients with stable COPD 
decrease median serum CRP levels 
greater than placebo, but it was not 
statistically significant. 
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Table 1 Baseline Characteristics 
 
Variable 
Erdosteine (n =19) Placebo (n =16)  
p-value Number 
(%) 
Mean ± SD 
Median  
(min-max) 
Number 
(%) 
Mean ± SD 
Median  
(min-max) 
Sex 
   Male   
 
19 (100) 
  
16 (93.7) 
  
0.09* 
Age (year)  68 (40-77)  65 (48-73) 0.26** 
Body weight (kg)  51.05 ± 9.77  50.06 ± 5.90 0.36*** 
Height (cm)  159.63 ± 6.35  157.63 ± 6.45 0.18*** 
BMI (kg/m2)  19.93 ± 2.94  20.1 ± 2.03 0.40*** 
Smoking status 
   Never smoker 
   Ex-smoker 
   Inactive smoker 
   Active smoker 
 
0 (0) 
18 (94.7) 
0 (0) 
1 (5.3) 
  
2 (12.5) 
12 (75) 
0 (0) 
2 (12.5) 
 0.49* 
Pack-years  
   0-20 
   21-40 
   41-60 
    ≥ 61 
 
7 (36.8) 
11 (57.9) 
0 (0) 
1 (5.3) 
  
7 (43.8) 
7 (43.8) 
0 (0) 
2 (12.5) 
 0.50* 
GOLD severity 
   GOLD 1 
   GOLD 2 
   GOLD 3 
   GOLD 4 
 
0 (0) 
8 (42.1) 
10 (52.6) 
1 (5.3) 
  
0 (0) 
5 (31.3) 
11 (68.8) 
0 (0) 
 0.23* 
Patient group 
   A 
   B 
   C 
   D 
 
3 (15.8) 
5 (26.3) 
7 (36.8) 
4 (21.1) 
  
4 (25) 
1 (6.1) 
8 (50) 
3 (18.8) 
 0.40* 
Routine therapy 
   None 
   Inhaler 
   bronchodilator 
   Oral bronchodilator 
   Bronchodilator   
   +ICS 
   Bronchodilator +   
   systemic  
   corticosteroids 
 
3 (15.8) 
 
0 (0) 
 
10 (52.6) 
0 (0) 
 
 
6 (31.6) 
  
1 (6.3) 
 
2 (12.5) 
 
6 (37.5) 
0 (0) 
 
 
7 (43.8) 
 0.50* 
FEV1 (Liter)  0.83 (0.50-1.74)  0.83(0.52-10.08) 0.40** 
FVC (Liter)  1.49 ± 0.56  1.48 ± 0.31 0.47*** 
FEV/FVC   0.63 (0.44-0.94)  0.62 (0.33-0.69) 0.07** 
FEV1 (% predicted)  0.45 ± 0.13  0.44 ± 0.12 0.35*** 
hs-CRP (mg/L)  1.14 (0.18-18)  0.77 (0.19-15.70) 0.32** 
Statin   0 (0)  0 (0)  
ACE inhibitor  0 (0)  1 (6.3) 0.13* 
ARB  0 (0)  0 (0)  
Beta blocker  0 (0)  0 (0)  
Vitamin E  0 (0)  0 (0)  
Arthritis   0 (0)  0 (0)  
Hypertension  4 (21.1)  5 (31.1) 0.38* 
SD: standard deviation, BMI: body mass index, ICS: inhaled corticosteroids; ACE inhibitor: angiotensin- 
converting enzyme inhibitor. ARB: angiotensin receptor blocker, FEV1: forced expiratory volume in one second, 
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FVC: forced vital capacity, *: Pearson chi-square/Fisher’s exact test/Kolmogorov Smirnov; **: Mann Whitney U 
test, *** Independent sample t-test 
 
Table 2 Serum CRP levels Erdosteine and Placebo Group 
 
Variable 
Erdosteine (n=19) Placebo (n=16)  
p-value Median  
(min-max) 
Mean rank Median  
(min-max) 
Mean rank 
hs-CRP serum 
(mg/L) 
     
   day 0 1.14 (0.18-18) 18.74 0.77 (0.19-15.7) 17.13 0.321* 
   day 11 1.44 (0.10-6.44) 20.08 0.74 (0.1-11.84) 15.53 0.095* 
   delta -0.10 (-16.16-+4.31)  0.005 (-11.7-+11.03)  0.275* 
* Mann Whitney U-test  
 
 
Table 3 Proportion of Subjects Experiencing Changes in Serum CRP levels in the placebo group and 
the erdosteine 
 Serum CRP Level p-value 
Decrease Increase 
n % n % 
Erdosteine 12 63.2 7 36.8 0.215* 
Placebo 8 50 8 50 
Total 20 57.2 15 42.8 
* Pearson chi-square 
Table 4 Serum CRP Level in Subpopulation COPD GOLD 3 
 
Variable 
Erdosteine (n=10) Placebo (n=11)  
p-value Median (min-max) mean rank Median (min-max) mean 
rank 
hs-CRP (mg/L)      
   day 0 2.75 (0.26-18) 13.3 0.73(0.19-15.7) 8.91 0.052* 
   day 11 1.14 (0.25-6.44) 11.55 0.99 (0.15-11.84 10.50 0.349* 
   delta -0.56 (-16.16-+0.44)  0.11 (-11.7- 11.03)  0.03* 
* Mann Whitney U-test 
Table 5 Proportion of Subjects Experiencing Changes in Serum CRP Levels in Subpopulation COPD 
GOLD 3 
 Serum CRP Level p-value 
Decrease Increase 
n % n % 
Erdosteine 7 70 3 30 0.095* 
Placebo 4 36.4 7 63.6 
Total 11 52.4 10 90.9 
* Fisher’s exact test 
Side effects that emerged during the study were shown in Table 6. 
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Table 6 Side Effects of Erdosteine 
Variable Erdosteine Placebo 
Central nervous system - 1 
Gastrointestinal 2 1 
Respiration - - 
Skin - - 
Others - - 
Total 2/19 (10%) 2/16 (6%) 
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